C
Carolina Simioni
Researcher at University of Ferrara
Publications - 37
Citations - 1499
Carolina Simioni is an academic researcher from University of Ferrara. The author has contributed to research in topics: PI3K/AKT/mTOR pathway & Protein kinase B. The author has an hindex of 18, co-authored 34 publications receiving 1176 citations.
Papers
More filters
Journal ArticleDOI
Oxidative stress: role of physical exercise and antioxidant nutraceuticals in adulthood and aging.
Carolina Simioni,Giorgio Zauli,Alberto M. Martelli,Marco Vitale,Gianni Sacchetti,Arianna Gonelli,Luca M. Neri +6 more
TL;DR: Three natural antioxidants, which are quercetin, resveratrol and curcumin, will be focused mainly on, as well as their benefits on physical activity and on aging, which is expected to increase through the years and can get favorable benefits from a constant exercise activity.
Journal ArticleDOI
Adenosine receptors and cancer
TL;DR: A review of the most relevant aspects of adenosine receptor subtype activation in tumors reported so far can be found in this paper, where it is shown that activation of A(2A) receptors leads to immunosuppressive effects, which decreases anti-tumoral immunity and thereby encourages tumor growth.
Journal ArticleDOI
Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells.
Stefania Merighi,Annalisa Benini,Prisco Mirandola,Stefania Gessi,Katia Varani,Carolina Simioni,Edward Leung,Stephen Maclennan,Pier Giovanni Baraldi,Pier Andrea Borea +9 more
TL;DR: Analysis of the effects of caffeine on HIF-1 protein accumulation and on VEGF and IL-8 expression in the human colon cancer cell line HT29 under hypoxic conditions provides evidence that adenosine could modulate the migration of colon cancer cells by an Hif-1α/VEGF/IL-8-dependent mechanism and that caffeine has the potential to inhibit Colon cancer cell growth.
Journal ArticleDOI
Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.
Luca M. Neri,Alice Cani,Am Martelli,Carolina Simioni,Christian Junghanss,Giovanna Tabellini,Francesca Ricci,P. L. Tazzari,Pasqualepaolo Pagliaro,James A. McCubrey,Silvano Capitani +10 more
TL;DR: It is pointed out that mTORC1 inhibitors, either as a single agent or in combination with Akt inhibitors, could represent a potential therapeutic innovative strategy in B-pre ALL.
Journal ArticleDOI
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.
Carolina Simioni,Luca M. Neri,Giovanna Tabellini,Francesca Ricci,Daniela Bressanin,Francesca Chiarini,Camilla Evangelisti,Alice Cani,P. L. Tazzari,Fraia Melchionda,Pasqualepaolo Pagliaro,Andrea Pession,James A. McCubrey,Silvano Capitani,Alberto M. Martelli,Alberto M. Martelli +15 more
TL;DR: The effects of the novel allosteric Akt inhibitor, MK-2206, on a panel of human T-ALL cell lines and primary cells from T-all patients indicate that Akt inhibition may represent a potential therapeutic strategy in T- ALL.